<DOC>
	<DOCNO>NCT02042599</DOCNO>
	<brief_summary>Describing pharmacokinetic model 48-h sevoflurane sedation ICU patient acute kidney failure</brief_summary>
	<brief_title>Pharmacokinetic Study 48-hour Sevoflurane Inhalation Using Disposable Delivery System ( AnaConDa© ) ICU Patients With Acute Kidney Injury</brief_title>
	<detailed_description>Prospective clinical monocentric study ICU sedate ventilated patient ( present acute kidney failure ) sevoflurane 48 h AnaConda® system , establish pharmacokinetic model sevoflurane metabolite ( hydroxyfluroisopropanol , fluoride )</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Sevoflurane</mesh_term>
	<criteria>Adult patient ventilate 48 h Stable respiratory hemodynamic condition Consent patient family Arterial line AKIN score = 3 BMI &lt; 30 Sevoflurane anaphylaxia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Sevoflurane</keyword>
	<keyword>Acute kidney injury</keyword>
	<keyword>Sedation</keyword>
	<keyword>ICU patient</keyword>
</DOC>